US · ZVRA · BIOTECHNOLOGY
Zevra Therapeutics, Inc. (ZVRA) intrinsic value and stock valuation
$8.76as of 2026-11-21 · Mkt cap 618.23M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Zevra Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values ZVRA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ZVRA’s statements →
Zevra Therapeutics, Inc. Graham Number
Graham Number: $9.73d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M | $28.7M |
| Operating income | -$-4.23M | -$-87M | -$-49.6M | -$-42.56M | $7.73M |
| Net income | $83.2M | -$-105.51M | -$-46.05M | -$-26.77M | -$-8.55M |
| EPSd | $1.45M | -$-2.28M | -$-1.3M | -$-776.17K | -$-287.2K |
| Operating cash flow | -$-1.6M | -$-69.67M | -$-33.53M | -$-18.72M | $10.4M |
| Capital expenditure | -$-830K | $0.00 | -$-300K | -$-90K | -$-100K |
| Free cash flow | -$-2.43M | -$-69.67M | -$-33.83M | -$-18.81M | $10.3M |
| Total assets | $284.7M | $178.1M | $172.3M | $115.3M | $132.9M |
| Total debt | $63.2M | $60.3M | $43.8M | $18.8M | $1.61M |
| Net debt | $800K | $26.5M | $720K | -$-46.69M | -$-110.74M |
| Total equity | $154.7M | $39.7M | $61.9M | $75.1M | $127.1M |
| Cash and short-term investments | $191M | $69.5M | $67.7M | $82.9M | $112.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M | $28.7M |
| Cost of revenue | $16.5M | $7.42M | $2.94M | $220K | $2.06M |
| Gross profit | $90M | $16.2M | $24.5M | $9.94M | $26.6M |
| Research and development expenses | $12.7M | $42.1M | $39.8M | $19.8M | $10.2M |
| Selling, general and administrative expenses | $77.6M | $54.9M | $35.1M | $15M | $8.7M |
| Other expenses | $3.86M | $6.24M | -$-780K | $17.7M | $0.00 |
| Operating expenses | $94.2M | $103.2M | $74.1M | $52.5M | $18.9M |
| Cost and expenses | $110.7M | $110.6M | $77.1M | $52.7M | $20.9M |
| Interest income | $6.95M | $2.17M | $4.54M | $1.51M | $260K |
| Interest expense | $7.98M | $7.35M | $1.5M | $340K | $380K |
| Depreciation and amortization | $4.05M | $6.39M | $1.01M | $940K | $260K |
| Ebitda | $98.7M | -$-76.4M | -$-43.54M | -$-25.53M | -$-7.89M |
| Operating income | -$-4.23M | -$-87M | -$-49.6M | -$-42.56M | $7.73M |
| Total other income/expenses, net | $90.9M | -$-3.14M | $3.56M | $15.8M | -$-16.25M |
| Income before tax | $86.7M | -$-90.14M | -$-46.05M | -$-26.8M | -$-8.52M |
| Income tax expense | $3.45M | $15.4M | $0.00 | -$-30K | $30K |
| Net income | $83.2M | -$-105.51M | -$-46.05M | -$-26.77M | -$-8.55M |
| Weighted average shares outstanding | $55.3M | $46.3M | $35.5M | $34.5M | $29.8M |
| Weighted average diluted shares outstanding | $57.3M | $46.3M | $35.5M | $34.5M | $29.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $191M | $69.5M | $67.7M | $82.9M | $112.4M |
| Net receivables | $23.3M | $10.5M | $17.4M | $8.3M | $1.53M |
| Inventory | $1.74M | $1.97M | $24.1M | $0.00 | $0.00 |
| Total current assets | $223M | $86M | $86.9M | $92.8M | $115.1M |
| Property, plant and equipment, net | $1.7M | $1.01M | $1.53M | $1.78M | $2.02M |
| Goodwill and intangible assets | $11.1M | $73.7M | $73.9M | $0.00 | $0.00 |
| Long-term investments | $47.9M | $6.01M | $0.00 | $20M | $15.4M |
| Total non-current assets | $61.7M | $92.1M | $85.4M | $22.5M | $17.9M |
| Total assets | $284.7M | $178.1M | $172.3M | $115.3M | $132.9M |
| Accounts payable | $2.48M | $13.1M | $14M | $3.61M | $520K |
| Short-term debt | $420K | $420K | $38.2M | $5.13M | $370K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $39.3M | $34.1M | $73.7M | $12M | $4.23M |
| Long-term debt | $62.8M | $59.9M | $5.52M | $13.6M | $1.24M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $90.8M | $104.4M | $36.7M | $28.2M | $1.59M |
| Capital lease obligations | $1.28M | $790K | $1M | $1.32M | $1.61M |
| Total liabilities | $130.1M | $138.5M | $110.5M | $40.2M | $5.82M |
| Common stock | $10K | $10K | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-422.06M | -$-505.29M | -$-399.78M | -$-353.73M | -$-267.03M |
| Accumulated other comprehensive income (loss) | -$-760K | $630K | -$-40K | $110K | -$0.00 |
| Total equity | $154.7M | $39.7M | $61.9M | $75.1M | $127.1M |
| Total investments | $176.5M | $41.7M | $24.7M | $37.4M | $15.4M |
| Total debt | $63.2M | $60.3M | $43.8M | $18.8M | $1.61M |
| Net debt | $800K | $26.5M | $720K | -$-46.69M | -$-110.74M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $83.2M | -$-105.51M | -$-46.05M | -$-41.54M | -$-8.55M |
| Depreciation and amortization | $4.05M | $6.39M | $1.01M | $940K | $260K |
| Stock-based compensation | $12.6M | $14.9M | $5.95M | $4.29M | $2.44M |
| Change in working capital | -$-26.51M | -$-6.64M | $5.88M | -$-410K | -$-360K |
| Accounts receivable | -$-11.98M | $6.87M | -$-9.08M | -$-6.77M | $1.05M |
| Inventory | -$-1.3M | -$-8.87M | $210K | $150K | $0.00 |
| Accounts payable | -$-15.59M | -$-3.6M | $11.1M | $3.13M | -$-1.11M |
| Net cash provided by operating activities | -$-1.6M | -$-69.67M | -$-33.53M | -$-18.72M | $10.4M |
| Investments in property, plant and equipment | -$-830K | $0.00 | -$-300K | -$-90K | -$-100K |
| Acquisitions, net | $0.00 | $0.00 | -$-30.4M | -$-14.09M | $0.00 |
| Net cash used for investing activities | $18.1M | -$-22.16M | -$-17.39M | -$-36.72M | -$-15.52M |
| Common stock issued | $12.4M | $64.5M | $6.32M | $320K | $49.3M |
| Common stock repurchased | $0.00 | $0.00 | -$-3.45M | -$-4.72M | -$-2.81M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $12.1M | $82.1M | $28.5M | $8.35M | $113.1M |
| Net change in cash | $28.6M | -$-9.26M | -$-22.42M | -$-46.88M | $108M |
| Cash at end of period | $62.4M | $33.8M | $43.1M | $65.5M | $112.4M |
| Operating cash flow | -$-1.6M | -$-69.67M | -$-33.53M | -$-18.72M | $10.4M |
| Capital expenditure | -$-830K | $0.00 | -$-300K | -$-90K | -$-100K |
| Free cash flow | -$-2.43M | -$-69.67M | -$-33.83M | -$-18.81M | $10.3M |
Line items
Line items
Line items
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
- CEO
- Neil F. McFarlane
- Employees
- 61
- Beta
- 0.85
Explore
Frequently asked questions
What is the intrinsic value of Zevra Therapeutics, Inc. (ZVRA)?
Zevra Therapeutics, Inc. (ZVRA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ZVRA undervalued?
ZVRA trades at a price of $8.76 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.